Autologous Anti-CD19 CAR T Cells KITE-197
autologous anti-cd19 car t cells kite-197
A preparation of autologous T-lymphocytes that have been genetically engineered to express a chimeric antigen receptor (CAR) specific for the tumor-associated antigen (TAA) CD19, with potential immunomodulating and antineoplastic activities. Upon administration, autologous anti-CD19 CAR T-cells KITE-197 specifically recognize and kill tumor cells expressing CD19. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.